CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
(CISTO Trial)
Trial Summary
What is the purpose of this trial?
Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US (1). Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians. The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study has the potential to fill these critical evidence gaps, change care pathways for the management of NMIBC (non-muscle-invasive bladder cancer), and provide for personalized, patient-centered care. The purpose of CISTO is to conduct a large prospective study that directly compares the impact of medical management versus bladder removal in recurrent high-grade NMIBC patients with BCG (Bacillus Calmette-Guerin) failure on clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs).
Research Team
John L Gore, MD
Principal Investigator
University of Washington
Eligibility Criteria
Inclusion Criteria
Treatment Details
Interventions
- Bladder Removal (Surgery)
- Medical Management (Behavioural Intervention)
- Standardized Patient-Reported Outcomes (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor
Dr. Timothy H. Dellit
University of Washington
Chief Executive Officer since 2023
MD from University of Washington
Dr. Anneliese Schleyer
University of Washington
Chief Medical Officer since 2023
MD, MHA
Patient-Centered Outcomes Research Institute
Collaborator
Nakela L. Cook
Patient-Centered Outcomes Research Institute
Chief Executive Officer since 2020
MD, MPH
Harv Feldman
Patient-Centered Outcomes Research Institute
Chief Medical Officer
MD, MSCE